AVIR - Atea Pharmaceuticals Announces Participation at Upcoming Investor Conferences | Benzinga
BOSTON, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that members of the Atea management team will participate in and present a business update at the following investor conferences in November.
- Jefferies London Healthcare Conference, Company Presentation on Wednesday, November 15, 2023 at 11:00 a.m. GMT / 7:00 a.m. ET
- 6th Annual Evercore ISI HealthCONx Conference, Fireside Chat on Wednesday, November 29, 2023 at 3:00 p.m. ET
Live webcasts of the presentations will be available on the Company's website at https://ir.ateapharma.com/. An archived webcast will be available on Atea Pharmaceuticals' website for at least 90 days following the event.
About Atea Pharmaceuticals
Atea is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing oral antiviral therapies to address the unmet medical needs of patients with serious viral infections. Leveraging the Company's deep understanding of antiviral drug development, nucleos(t)ide chemistry, biology, biochemistry and virology, Atea has built a proprietary nucleos(t)ide prodrug platform to develop novel ...